prikaz prve stranice dokumenta Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
  Download
PDF 2.35 MB
Scientific paper - Review paper
Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
International Journal of Molecular Sciences, 25 (2024), 3; 1517. https://doi.org/10.3390/ijms25031517
Eržen, Stjepan; Tonin, Gašper; Jurišić Eržen, Dubravka; Klen, Jasna

Cite this document

Eržen, S., Tonin, G., Jurišić Eržen, D. & Klen, J. (2024). Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. International Journal of Molecular Sciences, 25. (3). doi: 10.3390/ijms25031517

Eržen, Stjepan, et al. "Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity." International Journal of Molecular Sciences, vol. 25, no. 3, 2024. https://doi.org/10.3390/ijms25031517

Eržen, Stjepan, Gašper Tonin, Dubravka Jurišić Eržen and Jasna Klen. "Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity." International Journal of Molecular Sciences 25, no. 3 (2024). https://doi.org/10.3390/ijms25031517

Eržen, S., et al. (2024) 'Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity', International Journal of Molecular Sciences, 25(3). doi: 10.3390/ijms25031517

Eržen S, Tonin G, Jurišić Eržen D, Klen J. Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. International Journal of Molecular Sciences [Internet]. 2024 January 26 [cited 2024 November 12];25(3). doi: 10.3390/ijms25031517

S. Eržen, G. Tonin, D. Jurišić Eržen and J. Klen, "Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity", International Journal of Molecular Sciences, vol. 25, no. 3, January 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:095919. [Accessed: 12 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity
AuthorStjepan Eržen
AuthorGašper Tonin
AuthorDubravka Jurišić Eržen
AuthorJasna Klen
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Diabetes mellitus is a devastating chronic metabolic disease. Since the majority of type 2 diabetes mellitus patients are overweight or obese, a novel term—diabesity—has emerged. The gut–brain axis plays a critical function in maintaining glucose and energy homeostasis and involves a variety of peptides. Amylin is a neuroendocrine anorexigenic polypeptide hormone, which is co-secreted with insulin from β-cells of the pancreas in response to food consumption. Aside from its effect on glucose homeostasis, amylin inhibits homeostatic and hedonic feeding, induces satiety, and decreases body weight. In this narrative review, we summarized the current evidence and ongoing studies on the mechanism of action, clinical pharmacology, and applications of amylin and its analogs, pramlintide and cagrilintide, in the field of diabetology, endocrinology, and metabolism disorders, such as obesity.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 25, no. 3, 1517
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms25031517
URN:NBNurn:nbn:hr:184:095919
Publication2024-01-26
Document URLhttps://www.mdpi.com/1422-0067/25/3/1517
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-02-20 10:46:32